Jefferies analyst Chris Howerton downgraded Iveric bio to Hold from Buy with a price target of $20, down from $30.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ISEE:
- Iveric bio reports Q3 EPS (35c), consensus (40c)
- IVERIC bio put volume heavy and directionally bearish
- Iveric bio upgraded to Neutral at B. Riley after competitor in GA ‘disappoints’
- Iveric bio upgraded to Neutral from Sell at B. Riley
- Apellis, Iveric’s strategic value increased by NGM failure, says Credit Suisse